AGMB
AgomAb Therapeutics NV
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Last price
13.25
▼ 0.18 (1.34%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Tool
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
13.50
Prev close
13.43
Day high
13.64
Day low
13.07
Volume
68.36K
Market cap
$652.54M
P/E (TTM)
—
52W range
8.75 – 17.82
Day trading desk
Gap from prior close
+0.52%
Prior close 13.43
VWAP
13.25
+0.02% from price
Relative volume
0.67×
Normal
Session range
4.40%
13.06 – 13.64
Position in range
32%
Mid range
ATR (14D)
1.02
7.70% of price
Prior day high
13.85
PDH
Prior day low
13.01
PDL
Bid / ask spread
—
Quote not published
Session volume
67.61K
Avg 101.23K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
+0.23%
+1.6%
1M
+2.16%
-1.6%
3M
+21.12%
+18.0%
6M
-14.52%
-25.6%
YTD
-9.56%
-21.8%
1Y
—
-20.0%
3Y
—
-74.2%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on AGMB open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
2.40M
Total on file
Fundamentals
Market cap$652.54M
Enterprise value$462.23M
Revenue (TTM)—
Gross profit—
EBITDA$-65.56M
Net income$-81.60M
EPS (TTM)$-1.58
Free cash flow—
Total cash$251.98M
Total debt$1.14M
Book value / share$2.65
Shares outstanding49.25M
Float11.45M
Short % of float2.96%
Dividend yield—
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E-6.74
PEG ratio—
Price / sales—
Price / book5.00
EV / revenue—
EV / EBITDA-7.05
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity—
Return on assets—
Debt / equity0.43
Current ratio12.88
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | — |
| Research & development | $48.88M | $39.31M | $26.31M | $19.42M | +24.3% |
| Selling, general & admin | $12.57M | $9.82M | $6.00M | $4.49M | +28.0% |
| Total operating expense | $59.27M | $48.02M | $31.19M | $22.63M | +23.4% |
| Operating income | -$59.27M | -$48.02M | -$31.19M | -$22.63M | -23.4% |
| Net interest income | $1.55M | $1.14M | $210.00K | $25.00K | +35.5% |
| Pre-tax income | -$62.55M | -$46.26M | -$12.01M | -$10.81M | -35.2% |
| Tax provision | $0 | $4.00K | -$619.00K | -$2.66M | -100.0% |
| Net income | -$62.55M | -$46.27M | -$11.39M | -$8.14M | -35.2% |
| Net income to common | -$62.55M | -$46.27M | -$11.39M | -$8.14M | -35.2% |
| Basic EPS | -1.28 | -1.28 | -0.31 | -0.22 | -0.5% |
| Diluted EPS | -1.28 | -1.28 | -0.31 | -0.22 | -0.5% |
| EBIT | -$62.49M | -$46.20M | -$11.98M | -$10.76M | -35.3% |
| EBITDA | -$62.27M | -$45.88M | -$11.88M | -$10.74M | -35.7% |
| Basic shares | 48.74M | 36.24M | 36.24M | 36.24M | +34.5% |
| Diluted shares | 48.74M | 36.24M | 36.24M | 36.24M | +34.5% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $86.42M | $171.46M | $122.40M | $27.67M | — | -49.6% |
| Cash & short-term investments | $116.51M | $171.46M | $122.40M | $67.67M | — | -32.0% |
| Total current assets | $121.24M | $173.84M | $139.47M | $71.08M | — | -30.3% |
| Property, plant & equipment | $1.59M | $1.99M | $1.61M | $62.00K | — | -20.4% |
| Goodwill & intangibles | $28.72M | $28.72M | $28.72M | $28.72M | — | 0.0% |
| Total assets | $153.71M | $206.36M | $171.26M | $101.00M | — | -25.5% |
| Total current liabilities | $18.59M | $9.13M | $10.88M | $29.72M | — | +103.7% |
| Long-term debt | — | — | — | — | $690.00K | — |
| Total debt | $1.25M | $1.54M | $1.62M | $62.00K | — | -18.8% |
| Total liabilities | $22.80M | $18.28M | $19.82M | $34.75M | — | +24.8% |
| Retained earnings | -$181.71M | -$119.18M | -$72.83M | -$61.44M | — | -52.5% |
| Shareholder equity | $130.90M | $188.08M | $151.44M | $66.25M | — | -30.4% |
| Working capital | $102.65M | $164.72M | $128.59M | $41.37M | — | -37.7% |
| Net tangible assets | $102.18M | $159.36M | $122.71M | $37.53M | — | -35.9% |
| Shares issued | 48.74M | 48.74M | 48.74M | 48.74M | — | 0.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$62.55M | -$46.27M | -$11.39M | -$8.14M | -35.2% |
| Depreciation & amortisation | $219.00K | $311.00K | $99.00K | $23.00K | -29.6% |
| Stock-based compensation | $5.36M | $1.07M | $2.16M | $2.21M | +400.0% |
| Change in working capital | $406.00K | -$1.28M | $4.12M | $1.41M | +131.7% |
| Operating cash flow | -$51.74M | -$46.83M | -$24.59M | -$18.97M | -10.5% |
| Capital expenditure | -$4.00K | -$675.00K | — | — | +99.4% |
| Investing cash flow | -$33.00M | -$675.00K | $40.00M | -$44.59M | -4,789.5% |
| Financing cash flow | -$338.00K | $96.76M | $79.32M | $37.63M | -100.3% |
| Free cash flow | -$51.74M | -$47.50M | -$24.59M | -$18.97M | -8.9% |
| End cash position | $86.42M | $171.46M | $122.40M | $27.67M | -49.6% |
| Line item | 2025-12-31 | 2025-09-30 | 2024-12-31 | YoY |
|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | — |
| Research & development | $13.86M | $12.99M | $10.73M | +6.7% |
| Selling, general & admin | $3.25M | $2.64M | $1.38M | +23.4% |
| Total operating expense | $16.53M | $15.36M | $11.81M | +7.6% |
| Operating income | -$16.53M | -$15.36M | -$11.81M | -7.6% |
| Net interest income | $717.00K | $49.00K | $616.00K | +1,363.3% |
| Pre-tax income | -$17.40M | -$18.28M | -$11.73M | +4.8% |
| Tax provision | $0 | $0 | $4.00K | — |
| Net income | -$17.40M | -$18.28M | -$11.73M | +4.8% |
| Net income to common | -$17.40M | -$18.28M | -$11.73M | +4.8% |
| EBIT | -$17.54M | -$18.15M | -$11.88M | +3.4% |
| EBITDA | -$17.62M | -$18.05M | -$11.80M | +2.3% |
| Line item | 2026-06-30 | 2025-12-31 | 2025-09-30 | 2024-12-31 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $221.59M | $86.42M | $129.59M | $171.46M | +156.4% |
| Cash & short-term investments | $251.98M | $116.51M | $129.59M | $171.46M | +116.3% |
| Total current assets | $258.48M | $121.24M | $133.01M | $173.84M | +113.2% |
| Property, plant & equipment | $1.41M | $1.59M | $1.68M | $1.99M | -11.4% |
| Goodwill & intangibles | $28.72M | $28.72M | $28.72M | $28.72M | 0.0% |
| Total assets | $290.92M | $153.71M | $165.63M | $206.36M | +89.3% |
| Total current liabilities | $20.07M | $18.59M | $9.51M | $9.13M | +8.0% |
| Total debt | $1.14M | $1.25M | $1.33M | $1.54M | -9.2% |
| Total liabilities | $25.55M | $22.80M | $18.70M | $18.28M | +12.0% |
| Retained earnings | -$212.62M | -$181.71M | -$164.27M | -$119.18M | -17.0% |
| Shareholder equity | $265.38M | $130.90M | $146.93M | $188.08M | +102.7% |
| Working capital | $238.41M | $102.65M | $123.50M | $164.72M | +132.3% |
| Net tangible assets | $236.65M | $102.18M | $118.21M | $159.36M | +131.6% |
| Shares issued | 49.25M | 48.74M | 48.74M | 48.74M | +1.0% |
| Line item | 2025-12-31 | 2025-09-30 | 2024-12-31 | YoY |
|---|---|---|---|---|
| Net income | -$17.40M | -$18.28M | -$11.73M | +4.8% |
| Depreciation & amortisation | -$83.00K | $107.00K | $85.00K | -177.6% |
| Stock-based compensation | $1.42M | $1.34M | $499.00K | +6.1% |
| Change in working capital | $1.37M | $127.00K | -$1.62M | +978.7% |
| Operating cash flow | -$13.17M | -$13.64M | -$12.44M | +3.4% |
| Capital expenditure | — | — | -$363.00K | — |
| Investing cash flow | -$30.00M | $0 | -$363.00K | — |
| Financing cash flow | -$34.00K | -$156.00K | $81.86M | +78.2% |
| Free cash flow | -$13.18M | -$13.64M | -$12.80M | +3.4% |
| End cash position | $86.42M | $129.59M | $171.46M | -33.3% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Dec 2025 | -41.04 | — | — |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.41 | 2 | $0 | — |
| Next quarter | -0.42 | 2 | $0 | — |
| Current year | -1.81 | 5 | $0 | 0.0% |
| Next year | -1.97 | 5 | $0 | 0.0% |
Analyst targets & ownership
Mean target$33.00
High target$36.00
Low target$28.00
Implied upside149.06%
Analyst count5
ConsensusSTRONG BUY
Strong buy / Buy2 / 4
Hold0
Sell / Strong sell0 / 0
Held by insiders5.90%
Held by institutions53.63%
Institutions holding35
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
13.90
-4.66% from price
SMA 20
13.63
-2.80% from price
SMA 50
12.80
+3.53% from price
SMA 100
11.93
+11.05% from price
SMA 200
—
—
EMA 12
13.65
-2.90% from price
EMA 26
13.40
-1.13% from price
EMA 50
12.99
+1.97% from price
RSI (14)
48.9
Neutral
MACD (12,26,9)
0.24
Hist -0.13
ATR (14)
1.02
7.70% of price
Realised vol 30D
65.6%
Annualised
Bollinger upper
15.17
20, 2σ
Bollinger lower
12.09
20, 2σ
50 / 200 cross
—
—
Trend bias
—
—
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.82
More volatile than market
Correlation to SPY
0.27
Largely independent
Realised vol 30D
65.6%
Annualised
Market vol 1Y
13.9%
SPY, annualised
Max drawdown 1Y
-40.7%
Peak to trough
Max drawdown 5Y
-40.7%
Peak to trough
ATR 14
1.02
7.70% of price
Beta (reported)
—
5Y monthly, from filing
Short interest
Shares short
1.20M
Prior 1.24M
Change vs prior
-3.0%
Shorts covering
% of float
2.96%
Normal
% of shares out
2.45%
Against total outstanding
Days to cover
14.5
Crowded exit
Float
11.45M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 19, 26 | Cantor Fitzgerald | INITIATED | — | Overweight |
| Jul 23, 26 | B. Riley Securities | INITIATED | — | Buy |
| Jun 22, 26 | HC Wainwright & Co. | INITIATED | — | Buy |
| Mar 3, 26 | Leerink Partners | INITIATED | — | Outperform |
| Mar 3, 26 | JP Morgan | INITIATED | — | Overweight |
| Mar 3, 26 | Morgan Stanley | INITIATED | — | Overweight |
SEC filings
Corporate Changes & Voting Matters
6-K · 2026-08-10
Corporate Changes & Voting Matters
6-K · 2026-08-06
Corporate Changes & Voting Matters
6-K · 2026-06-23
Corporate Changes & Voting Matters
6-K · 2026-05-27
Corporate Changes & Voting Matters
6-K · 2026-04-24
Periodic Financial Reports
20-F · 2026-04-23
Offering Registrations
S-8 · 2026-03-11
Corporate Changes & Voting Matters
6-K · 2026-03-05
Headlines
Cantor Fitzgerald Initiates AgomAb Therapeutics at Overweight
MT Newswires · 4d ago
Agomab Announces Proposed Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors
GlobeNewswire · 13d ago
Agomab Reports Half Year 2026 Financial Results and Confirms 2026 Outlook
GlobeNewswire · 17d ago
B. Riley Initiates AgomAb Therapeutics at Buy With $34 Price Target
MT Newswires · 31d ago
Is AgomAB Therapeutics NV (AGMB) Stock a Biotech Opportunity With Targeted Tissue Therapy Potential?
Insider Monkey · 52d ago
European Equities Traded in the US as American Depositary Receipts Decline Friday
MT Newswires · 58d ago
Agomab Therapeutics Shares NOV-ERA Phase 2b Study Design With Ontunisertib in Fibrostenosing Crohn's Disease
MT Newswires · 61d ago
Agomab Announces Design of NOV-ERA Phase 2b Study with Ontunisertib in Fibrostenosing Crohn’s Disease
GlobeNewswire · 61d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.